Depomed Rejects Horizon Pharma's Takeover Attempt, Again

Source: Reuters

Jul 30, 2015

California-based Depomed Inc. rejected a revised, $33 per share hostile takeover proposal from Horizon Pharma, saying it undervalues the company.

Dublin-based Horizon Pharma first approached rival Depomed in May and after being rejected, went public with an unsolicited offer valued at $29.25 per share in July. Depomed rejected the offer, adopting a poison pill -- or shareholder rights plan -- to discourage takeover without the board's approval.

Depomed’s board said in a press statement that Horizon's higher offer merely reflects the rise in Depomed's stock price and is not a true increase.

According to Reuters, Horizon Pharma has said that it will now "consider other options to pressure Depomed."

Read the Reuters press release

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments